S-FILM Orally Disintegrating Strip
Overall, the study met its co-primary end points, with VYBRIQUE demonstrating superior improvements in sexual function vs placebo. Pharmacokinetic data also showed that peak plasma concentrations were reached between 30 and 300 minutes under fasting conditions.
How To Use S-FILM Orally Disintegrating Strip
Overall, the study met its co-primary end points, with VYBRIQUE demonstrating superior improvements in sexual function vs placebo. Pharmacokinetic data also showed that peak plasma concentrations were reached between 30 and 300 minutes under fasting conditions. The median time to peak plasma concentrations was 80 minutes. “While awareness and open discussion around ED have grown, it’s still a sensitive topic where many men value discretion,” added Nicholas Hart, IBSA USA CEO, in the news release.1 “The FDA approval of VYBRIQUE provides men experiencing ED with a novel treatment option that helps meet the evolving needs of patients today.” The sildenafil oral film is expected to be commercially available in the US in March 2026. IBSA also reported that direct home delivery of VYBRIQUE will be available in all states, “providing patients a convenient fulfillment option.” Commenting on the approval to Urology Times, Justin Dubin, MD, said, “As men continue to face stigma around men’s health – especially erectile dysfunction – it’s encouraging to see more discreet, patient-centered treatment options become available.
More common
Fast-acting PDE5 inhibitor troches with sublingual or buccal absorption have been available through compounding pharmacies for years, but they’ve lacked FDA approval. With the FDA now approving a fast-acting, easy-to-use ED therapy, this represents a meaningful step forward in patient care and reinforces a commitment to privacy, discretion, and efficiency in both treatment and medication delivery.” Dubin is director of Men’s Sexual Health at Baptist Health Miami Cancer Institute in Florida. Amy Pearlman, MD, a board-certified urologist with expertise in sexual, hormonal, and genitourinary health from South Florida, also spoke to the convenience of the oral film and its implications for patient care. “The FDA approval of Vybrique is genuinely exciting and adds a fresh option to the ED treatment space. What stands out is how easy it is for patients to use: it can be taken with or without food, there’s no need for water, it dissolves sildenafil 25mg tablets in the mouth, and it works faster than traditional sildenafil pills. The median time to peak plasma concentrations was 80 minutes. “While awareness and open discussion around ED have grown, it’s still a sensitive topic where many men value discretion,” added Nicholas Hart, IBSA USA CEO, in the news release.1 “The FDA approval of VYBRIQUE provides men experiencing ED with a novel treatment option that helps meet the evolving needs of patients today.” The sildenafil oral film is expected to be commercially available in the US in March 2026.
| Aspect | Strips | Tablets |
|---|---|---|
| Mode of Administration | Sublingual, dissolved in mouth | Oral, swallowed whole |
| Onset of Action | Faster (within 15 minutes) | Slightly slower (30-60 minutes) |
| Dosing Flexibility | Precise, customizable doses | Fixed dose per tablet |
| Convenience | Easy for those with swallowing difficulties | May require water |
| Storage | Compact, no need for water | Requires water for swallowing |
IBSA also reported that direct home delivery of VYBRIQUE will be available in all states, “providing patients a convenient fulfillment option.” Commenting on the approval to Urology Times, Justin Dubin, MD, said, “As men continue to face stigma around men’s health – especially erectile dysfunction – it’s encouraging to see more discreet, patient-centered treatment options become available. Fast-acting PDE5 inhibitor troches with sublingual or buccal absorption have been available through compounding pharmacies for years, but they’ve lacked FDA approval. With the FDA now approving a fast-acting, easy-to-use ED therapy, this represents a meaningful step forward in patient care and reinforces a commitment to privacy, discretion, and efficiency in both treatment and medication delivery.” Dubin is director of Men’s Sexual Health at Baptist Health Miami Cancer Institute in Florida. Amy Pearlman, MD, a board-certified urologist with expertise in sexual, hormonal, and genitourinary health from South Florida, also spoke to the convenience of the oral film and its implications for patient care.
- Sildenafil oral strips provide a non-invasive way to treat ED.
- They avoid swallowing pills, which some patients find difficult.
- Strips are often manufactured with pleasant flavors to enhance appeal.
- The medication’s effect can be influenced by food intake.
- Alcohol consumption may reduce effectiveness or increase side effects.
- Sildenafil strips should be used as prescribed and not mixed with other ED drugs.
- These strips are designed for quick absorption in the oral mucosa.
- Overuse or misuse can lead to adverse health effects.
- Proper dosing helps minimize risks of prolonged erections or priapism.
- Sildenafil strips do not cure ED but help manage symptoms.
- They may be used in combination with psychological or lifestyle interventions.
- Always check expiration dates before using sildenafil strips.
“The FDA approval of Vybrique is genuinely exciting and adds a fresh option to the ED treatment space. What stands out is how easy it is for patients to use: it can be taken with or without food, there’s no need for water, it dissolves sildenafil 25mg tablets in the mouth, and it works faster than traditional sildenafil pills. Those details matter, especially when spontaneity and convenience are a big part of sexual health,” she explained. “My patients are always asking about new and innovative therapies.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Viagra Generic | 150mg | 120 + 8 Pills | 177.58€ 169.12€ | |
| Viagra Generic | 100mg | 90 + 6 Pills | 129.02€ 122.88€ | |
| Viagra Generic | 200mg | 90 + 6 Pills | 170.79€ 162.66€ | |
| Viagra Generic | 50mg | 90 + 6 Pills | 107.37€ 102.26€ | |
| Kamagra Soft Tabs | 100mg | 12 Pills | 57.55€ 54.81€ | |
| Viagra Generic | 100mg | 270 + 10 Pills | 270.47€ 257.59€ | |
| Viagra Generic | 150mg | 60 + 4 Pills | 111.25€ 105.95€ | |
| Viagra Generic | 50mg | 20 Pills | 40.52€ 38.59€ | |
| Kamagra | 100mg | 20 Pills | 86.09€ 81.99€ | |
| Viagra Generic | 200mg | 60 + 4 Pills | 125.19€ 119.23€ | |
| Viagra Generic | 100mg | 20 Pills | 45.58€ 43.41€ | |
| Kamagra Soft Tabs | 100mg | 84 + 4 Pills | 233.05€ 221.95€ | |
| Kamagra | 100mg | 12 Pills | 55.64€ 52.99€ |
I’m looking forward to seeing how Vybrique performs in the real world and how it fits into everyday clinical practice as another way to personalize care.” IBSA USA announces FDA approval of VYBRIQUE™, the first and only oral film to treat men with erectile dysfunction. National Institute of Diabetes and Digestive and Kidney Disease. A new sildenafil oral film in patients with erectile dysfunction. Back to Journals » Drug Design, Development and Therapy » Volume 11 Authors Radicioni M, Castiglioni C , Giori A , Cupone I , Frangione V , Rovati S Editor who approved publication: Dr Sukesh Voruganti Milko Radicioni,1 Chiara Castiglioni,1 Andrea Giori,2 Irma Cupone,3 Valeria Frangione,4 Stefano Rovati4 1CROSS Research S.A., Phase I Unit, Arzo, Switzerland; 2IBSA Farmaceutici Italia, Lodi, Italy; 3Bouty S.p.A., Strada Padana Superiore, Cassina De’ Pecchi, Italy; 4IBSA Institut Biochimique S.A., Pambio-Noranco, Switzerland Abstract: A new orodispersible film formulation of the phosphodiesterase type 5 inhibitor, sildenafil, has been developed to examine the advantages of an orally disintegrating film formulation and provide an alternative to the current marketed products for the treatment of erectile dysfunction. The pharmacokinetics of the sildenafil 100 mg orodispersible film (IBSA) was compared to that of the conventional marketed 100 mg film-coated tablet (Viagra®) after single-dose administration to 53 healthy male volunteers (aged 18–51 years) in a randomized, open, two-way crossover bioequivalence study. Each subject received a single oral dose of 100 mg of sildenafil as test or reference formulation administered under fasting conditions at each of the two study periods according to a randomized crossover design. There was a washout interval of ≥7 days between the two administrations of the investigational medicinal products. Blood samples for pharmacokinetic analysis were collected up to 24 h post-dosing.
Sildenafil Strips price & minimum order quantity
Tadalafil has the longest t1/2 (~17.5 h), and the t1/2 for sildenafil and vardenafil is ~4 h. More than 25 years of clinical experience has confirmed the risk/benefit profile of sildenafil and established it as an effective treatment option for erectile dysfunction. Sildenafil could also be taken by men with comorbidities, such as hypertension, stable coronary artery disease, congestive heart failure, diabetes mellitus, traumatic spinal cord injury, obstructive sleep apnea, multiple sclerosis, renal dysfunction, prostate cancer, Parkinson’s disease, depression, and traumatic stress disorders.6 It is usually administered in doses of 25, 50, and 100 mg, with the recommended starting dose of 50 mg to be adapted according to response and side effects.1 Commonly reported adverse events (AEs) with sildenafil, as with the other available PDE5 inhibitors, include headache, flushing, dyspepsia, dizziness, and vision disturbances and are generally mild in nature and self-limiting.1 Since the expiry of Pfizer’s patent on sildenafil citrate for the treatment of erectile dysfunction in a number of European countries in 2013, several different formulations of sildenafil have become available. Orally disintegrating film and tablet formulations of PDE5 inhibitors that disintegrate in the patient’s mouth without the need for swallowing with water have been developed.7–12 Orodispersible films are defined as single or multilayer sheets of suitable materials, to be placed in the mouth where they disperse rapidly,13 requiring only a small amount of saliva on the tongue to dissolve within a few minutes of administration. In addition to not requiring water for administration, orodispersible films share the advantages of tablet formulations (accurate dosage and ease of administration) with those of liquid dosing forms (ease of swallowing and rapid bioavailability due to bypassing the hepatic first-pass effect when the absorption of active substance occurs mainly through the oral mucosae).
Can I take S-FILM for premature ejaculation?
Although orodispersible formulations have particular relevance by improving compliance in special patient populations, such as children, geriatric patients, and dysphasic patients who have difficulty in swallowing tablets or capsules, their convenience, superior dosing accuracy, and rapid onset of action contribute to strong patient preference over conventional solid dosage forms across a wide range of patient groups.14–16 Rapid dissolution, absorption, and onset of drug action are useful in motion sickness and sudden episodes of allergic attack of coughing, bronchitis, and asthma. Some drugs are absorbed from the mouth, pharynx, and esophagus: pre-gastric absorption can improve bioavailability with consequent reduction of dosage and unwanted effects. Orodispersible films have advantages over orally disintegrating tablet formulations, which may require more complicated and expensive manufacturing processes, have issues of hardness and friability during manufacturing, storage, handling and administration, and may present a risk of choking.16 Orodispersible films are thin and flexible, can be manufactured in a range of sizes and shapes, and are easily transported and stored. Research has shown that four out of five patients prefer orally disintegrating dosage forms over conventional solid oral dosage forms.15 As orodispersible film formulations do not require administration with water, they may provide additional benefit where comorbid conditions such as renal impairment, congestive heart failure, or other disorders impose a restriction on fluid intake, or where dysphagia creates difficulty with swallowing conventional film tablet dosage forms. The primary objective was to compare the rate (peak plasma concentration; Cmax) and extent (area under the curve [AUC] from administration to last observed concentration time; AUC0–t) of sildenafil absorption after single-dose administration of test and reference. Secondary endpoints were observed to describe the plasma pharmacokinetic profiles of sildenafil and its metabolite sildenafil softgel capsule N-desmethyl-sildenafil relative bioavailability and safety profile after single-dose administration. The mean sildenafil and N-desmethyl-sildenafil plasma concentration–time profiles up to 24 h after single-dose administration of sildenafil 100 mg orodispersible film and film-coated tablet were nearly superimposable. The bioequivalence test was fully satisfied for sildenafil and N-desmethyl-sildenafil in terms of rate and extent of bioavailability. Adverse events occurred at similar rates for the two formulations and were of mild-to-moderate severity. The results suggest that the new orodispersible film formulation can be used interchangeably with the conventional film-coated formulation. Keywords: sildenafil, pharmacokinetics, bioequivalence, orodispersible film, PDE5 inhibitor, N-desmethyl-sildenafil The first-in-class selective inhibitor of cyclic guanosine monophosphate-specific phosphodiesterase type 5 (PDE5), sildenafil, has become well established as a safe and effective treatment for male erectile dysfunction since the approval of Viagra® (Pfizer Ltd, Tadworth, UK) by the US Food and Drug Administration (FDA) in 1998. Guidelines on male sexual dysfunction established by the European Association of Urology recommend oral pharmacotherapy with PDE5 inhibitors as first-line therapy for erectile dysfunction.1 The PDE5 inhibitors sildenafil, tadalafil, vardenafil, and avanafil are sildenafil price ireland currently approved for use for erectile dysfunction.
Created by Medical Techs
The primary objective was to compare the rate (peak plasma concentration; Cmax) and extent (area under the curve [AUC] from administration to last observed concentration time; AUC0–t) of sildenafil absorption after single-dose administration of test and reference. Secondary endpoints were observed to describe the plasma pharmacokinetic profiles of sildenafil and its metabolite sildenafil softgel capsule N-desmethyl-sildenafil relative bioavailability and safety profile after single-dose administration. The mean sildenafil and N-desmethyl-sildenafil plasma concentration–time profiles up to 24 h after single-dose administration of sildenafil 100 mg orodispersible film and film-coated tablet were nearly superimposable. The bioequivalence test was fully satisfied for sildenafil and N-desmethyl-sildenafil in terms of rate and extent of bioavailability. Adverse events occurred at similar rates for the two formulations and were of mild-to-moderate severity.
5.2 Prolonged Erection and Priapism
The results suggest that the new orodispersible film formulation can be used interchangeably with the conventional film-coated formulation. Keywords: sildenafil, pharmacokinetics, bioequivalence, orodispersible film, PDE5 inhibitor, N-desmethyl-sildenafil The first-in-class selective inhibitor of cyclic guanosine monophosphate-specific phosphodiesterase type 5 (PDE5), sildenafil, has become well established as a safe and effective treatment for male erectile dysfunction since the approval of Viagra® (Pfizer Ltd, Tadworth, UK) by the US Food and Drug Administration (FDA) in 1998. Guidelines on male sexual dysfunction established by the European Association of Urology recommend oral pharmacotherapy with PDE5 inhibitors as first-line therapy for erectile dysfunction.1 The PDE5 inhibitors sildenafil, tadalafil, vardenafil, and avanafil are sildenafil price ireland currently approved for use for erectile dysfunction. Each PDE5 inhibitor has an individual pharmacokinetic and side effects profile, although no significant differences in efficacy among therapies are evident.1–5 The onset of action after oral administration of the available PDE5 inhibitors may be within 30 min; however, most men require at least 60 min delay after taking the medication (up to 2 h with tadalafil, while avanafil and vardenafil have the shortest onsets of action). Avanafil reaches peak plasma concentration (Cmax) 30–45 min after oral dosing and has a t1/2 of 1.1–1.23 h. Each PDE5 inhibitor has an individual pharmacokinetic and side effects profile, although no significant differences in efficacy among therapies are evident.1–5 The onset of action after oral administration of the available PDE5 inhibitors may be within 30 min; however, most men require at least 60 min delay after taking the medication (up to 2 h with tadalafil, while avanafil and vardenafil have the shortest onsets of action). Avanafil reaches peak plasma concentration (Cmax) 30–45 min after oral dosing and has a t1/2 of 1.1–1.23 h. Tadalafil has the longest t1/2 (~17.5 h), and the t1/2 for sildenafil and vardenafil is ~4 h. More than 25 years of clinical experience has confirmed the risk/benefit profile of sildenafil and established it as an effective treatment option for erectile dysfunction. Sildenafil could also be taken by men with comorbidities, such as hypertension, stable coronary artery disease, congestive heart failure, diabetes mellitus, traumatic spinal cord injury, obstructive sleep apnea, multiple sclerosis, renal dysfunction, prostate cancer, Parkinson’s disease, depression, and traumatic stress disorders.6 It is usually administered in doses of 25, 50, and 100 mg, with the recommended starting dose of 50 mg to be adapted according to response and side effects.1 Commonly reported adverse events (AEs) with sildenafil, as with the other available PDE5 inhibitors, include headache, flushing, dyspepsia, dizziness, and vision disturbances and are generally mild in nature and self-limiting.1 Since the expiry of Pfizer’s patent on sildenafil citrate for the treatment of erectile dysfunction in a number of European countries in 2013, several different formulations of sildenafil have become available.
| Parameter | Description | Typical Values | Notes |
|---|---|---|---|
| Absorption Time | Time to reach peak plasma levels | 15-30 minutes | Faster than tablets |
| Peak Plasma Concentration | Max concentration after dose | 120-250 ng/mL | Varies with dose |
| Half-life | Time for plasma levels to reduce by half | 3-5 hours | Limits dosing frequency |
| Bioavailability | Percentage of dose reaching systemic circulation | Approx. 80% | Enhanced via mucosal absorption |
Orally disintegrating film and tablet formulations of PDE5 inhibitors that disintegrate in the patient’s mouth without the need for swallowing with water have been developed.7–12 Orodispersible films are defined as single or multilayer sheets of suitable materials, to be placed in the mouth where they disperse rapidly,13 requiring only a small amount of saliva on the tongue to dissolve within a few minutes of administration. In addition to not requiring water for administration, orodispersible films share the advantages of tablet formulations (accurate dosage and ease of administration) with those of liquid dosing forms (ease of swallowing and rapid bioavailability due to bypassing the hepatic first-pass effect when the absorption of active substance occurs mainly through the oral mucosae). Although orodispersible formulations have particular relevance by improving compliance in special patient populations, such as children, geriatric patients, and dysphasic patients who have difficulty in swallowing tablets or capsules, their convenience, superior dosing accuracy, and rapid onset of action contribute to strong patient preference over conventional solid dosage forms across a wide range of patient groups.14–16 Rapid dissolution, absorption, and onset of drug action are useful in motion sickness and sudden episodes of allergic attack of coughing, bronchitis, and asthma.
- Sildenafil oral strips are a fast-acting form of erectile dysfunction medication.
- They are administered orally, dissolving quickly on the tongue for rapid effect.
- Sildenafil strips are often flavored to improve the user experience.
- They contain the same active ingredient as traditional sildenafil tablets.
- These strips are designed for people seeking discreet medication options.
- Onset of action for sildenafil strips can be within 15-30 minutes.
- Proper storage of sildenafil strips involves keeping them in a cool, dry place.
- Dosage strength varies, typically available in 25mg, 50mg, and 100mg.
- Using sildenafil strips without medical consultation is not recommended.
- They may interact with other medications like nitrates or alpha-blockers.
- Sildenafil oral strips are approved for the treatment of erectile dysfunction.
- Users should follow prescribed dosages for safety and effectiveness.
Some drugs are absorbed from the mouth, pharynx, and esophagus: pre-gastric absorption can improve bioavailability with consequent reduction of dosage and unwanted effects.
- Sildenafil strips are an alternative to traditional pill forms.
- The strips dissolve quickly, eliminating need for water to swallow.
- They are convenient for on-the-go use and discreet consumption.
- Possible side effects include headache, flushing, and dizziness.
- Sildenafil strips should be used approximately one hour before activity.
- Not suitable for individuals with certain health conditions; consult a doctor.
- They are typically used in men aged 18 and above.
- The medication works by increasing blood flow to the penis.
- Sildenafil strips can be part of a broader erectile dysfunction treatment plan.
- Side effects may vary depending on individual health status.
- Erectile response may improve with proper use and dosing.
- They are available through licensed pharmacies and online sources.
Orodispersible films have advantages over orally disintegrating tablet formulations, which may require more complicated and expensive manufacturing processes, have issues of hardness and friability during manufacturing, storage, handling and administration, and may present a risk of choking.16 Orodispersible films are thin and flexible, can be manufactured in a range of sizes and shapes, and are easily transported and stored.
Shipping Information
Research has shown that four out of five patients prefer orally disintegrating dosage forms over conventional solid oral dosage forms.15 As orodispersible film formulations do not require administration with water, they may provide additional benefit where comorbid conditions such as renal impairment, congestive heart failure, or other disorders impose a restriction on fluid intake, or where dysphagia creates difficulty with swallowing conventional film tablet dosage forms.
Tastylia 20 Mg
Those details matter, especially when spontaneity and convenience are a big part of sexual health,” she explained. “My patients are always asking about new and innovative therapies. I’m looking forward to seeing how Vybrique performs in the real world and how it fits into everyday clinical practice as another way to personalize care.” IBSA USA announces FDA approval of VYBRIQUE™, the first and only oral film to treat men with erectile dysfunction. National Institute of Diabetes and Digestive and Kidney Disease. A new sildenafil oral film in patients with erectile dysfunction.
6.2 Postmarketing Experience
Back to Journals » Drug Design, Development and Therapy » Volume 11 Authors Radicioni M, Castiglioni C , Giori A , Cupone I , Frangione V , Rovati S Editor who approved publication: Dr Sukesh Voruganti Milko Radicioni,1 Chiara Castiglioni,1 Andrea Giori,2 Irma Cupone,3 Valeria Frangione,4 Stefano Rovati4 1CROSS Research S.A., Phase I Unit, Arzo, Switzerland; 2IBSA Farmaceutici Italia, Lodi, Italy; 3Bouty S.p.A., Strada Padana Superiore, Cassina De’ Pecchi, Italy; 4IBSA Institut Biochimique S.A., Pambio-Noranco, Switzerland Abstract: A new orodispersible film formulation of the phosphodiesterase type 5 inhibitor, sildenafil, has been developed to examine the advantages of an orally disintegrating film formulation and provide an alternative to the current marketed products for the treatment of erectile dysfunction. The pharmacokinetics of the sildenafil 100 mg orodispersible film (IBSA) was compared to that of the conventional marketed 100 mg film-coated tablet (Viagra®) after single-dose administration to 53 healthy male volunteers (aged 18–51 years) in a randomized, open, two-way crossover bioequivalence study. Each subject received a single oral dose of 100 mg of sildenafil as test or reference formulation administered under fasting conditions at each of the two study periods according to a randomized crossover design. There was a washout interval of ≥7 days between the two administrations of the investigational medicinal products. Blood samples for pharmacokinetic analysis were collected up to 24 h post-dosing.